EyePoint Pharmaceuticals, Inc. (EYPT) Stock: Price, Forecast & Analyst Target
EyePoint Pharmaceuticals, Inc. (EYPT) — MoonshotScore 18/100 (Weak band), calculated Nov 18, 2026. Price $0.2642 (-2.87%), as of the Nov 19, 2026 trading session; market cap $30.1M.
Educational signal · not a buy or sell recommendation · How to read this
EyePoint Pharmaceuticals, Inc. · EYPT · NASDAQ
EyePoint Pharmaceuticals, Inc. focuses on developing and commercializing ophthalmic products for treating eye diseases. The company's portfolio includes treatments for diabetic macular edema, uveitis, and post-operative ocular inflammation, with a pipeline focused on sustained-release technologies.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · EyePoint Pharmaceuticals (EYPT)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a fragile balance sheet and stalling growth — broad distress, a capital-preservation call, not a value entry. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Strained; Valuation: Fair; Growth Durability: Shrinking; Momentum: Falling.
- quarterly revenue $756,000 (Q3 FY2026, quarter ended Sep 30, 2026)
- EPS beat 0 of the last 8 reports
- Altman Z -17.32 · Piotroski F 2
Holding back: weak fundamentals, balance-sheet strain, soft growth, weak price trend
Helping: an attractive price
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 17 | Weak | |
| 17 | Weak | |
| 23 | Weak | |
| 23 | Weak | |
| 18 | Weak | |
| 18 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.2642 | |
| Change on the day | -2.87% | |
| 52-week range | $0.2642 – $19.11 | |
| Market capitalisation | $30.1M | — |
| Shares traded on the day | 3.44M |
Price & events
Other perspectives
Council score for EyePoint Pharmaceuticals (EYPT): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 8, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is EyePoint Pharmaceuticals (EYPT), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. EyePoint Pharmaceuticals, Inc. (EYPT) is listed on NASDAQ. It employs 214 people and is led by Jay S. Duker. In Q3 FY2026 it reported revenue of $756,000 and net income of -$96M. The market values it at $30.1M.
What do the latest results show for EyePoint Pharmaceuticals (EYPT)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $756,000. Against analyst estimates the company has EPS beat 0 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $756,000 | -$96M | -$1.07 (diluted) |
| Q2 FY2026 | $507,000 | -$94M | -$1.09 (diluted) |
| Q1 FY2026 | $696,000 | -$85M | -$0.99 (diluted) |
| Q4 FY2025 | $620,000 | -$68M | -$0.81 (diluted) |
What are the financial strengths and risks for EyePoint Pharmaceuticals (EYPT)?
Short answer · as of
The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is weak fundamentals, balance-sheet strain, soft growth, weak price trend. The distress and quality screens read Altman Z -17.32 · Piotroski F 2. Trailing ratios: current ratio 3.30.
Data-derived red flags
- Listing risk — at $0.2642 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -17.32 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
What should you watch next at EyePoint Pharmaceuticals (EYPT)?
Short answer · as of
Current published price targets run low $0.50 · high $40.00 · consensus $11.21 · median $4.00 against a quoted price of $0.2642 (as of Nov 19, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How does EyePoint Pharmaceuticals compare with its peers?
Short answer
EyePoint Pharmaceuticals's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $12.17 Nov 19, 2026 | $861M | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| $30.78 Nov 19, 2026 | $1.03B | 64 5-pillar Nov 18, 2026 | |
| $8.14 Nov 19, 2026 | $796M | 63 5-pillar Nov 18, 2026 | |
| EyePoint Pharmaceuticals (EYPT) — this page | $0.2642 | $30.1M | 18 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $0.50 – $40.00
- Consensus target
- $11.21
- Median target
- $4.00
Consensus record · Captured .
Measured against a quoted price of $0.2642 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held EYPT in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported EYPT in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about EyePoint Pharmaceuticals (EYPT)?
Investor Questions: EYPT Stock
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for EYPT?
EYPT carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. EyePoint Pharmaceuticals, Inc. focuses on developing and commercializing ophthalmic products for treating eye diseases.
Is EYPT a good stock to buy?
Stock Expert AI does not rate EYPT buy, sell or hold. EyePoint Pharmaceuticals, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the EYPT stock price today?
The last price recorded for EyePoint Pharmaceuticals, Inc. (EYPT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the EYPT price target?
The analyst consensus price target for EyePoint Pharmaceuticals, Inc. (EYPT), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the key factors to evaluate for EYPT?
EyePoint Pharmaceuticals, Inc. (EYPT) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Strategic collaborations with Alimera Sciences, Bausch & Lomb, and Ocumension Therapeutics expand market reach and product development capabilities. Not financial advice.
How frequently does EYPT data refresh on this page?
EYPT's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven EYPT's recent stock price performance?
EyePoint Pharmaceuticals, Inc. (EYPT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative sustained-release drug delivery technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider EYPT overvalued or undervalued right now?
EyePoint Pharmaceuticals, Inc. (EYPT) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of EYPT?
Fractional-share availability for EyePoint Pharmaceuticals, Inc. (EYPT) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 19 figures on this page — 11 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com